首页> 外文期刊>Current pharmaceutical design >Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by 'molecular tweezers' - from the test tube to animal models.
【24h】

Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by 'molecular tweezers' - from the test tube to animal models.

机译:通过“分子镊子” - 从试管从试管扰乱淀粉样蛋白蛋白低聚物的自组装和毒性。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Despite decades of research, therapy for diseases caused by abnormal protein folding and aggregation (amyloidoses) is limited to treatment of symptoms and provides only temporary and moderate relief to sufferers. The failure in developing successful disease-modifying drugs for amyloidoses stems from the nature of the targets for such drugs - primarily oligomers of amyloidogenic proteins, which are distinct from traditional targets, such as enzymes or receptors. The oligomers are metastable, do not have well-defined structures, and exist in dynamically changing mixtures. Therefore, inhibiting the formation and toxicity of these oligomers likely will require out-of-the-box thinking and novel strategies. We review here the development of a strategy based on targeting the combination of hydrophobic and electrostatic interactions that are key to the assembly and toxicity of amyloidogenic proteins using lysine (K)-specific "molecular tweezers" (MTs). Our discussion includes a survey of the literature demonstrating the important role of K residues in the assembly and toxicity of amyloidogenic proteins and the development of a lead MT derivative called CLR01, from an inhibitor of protein aggregation in vitro to a drug candidate showing effective amelioration of disease symptoms in animal models of Alzheimer's and Parkinson's diseases.
机译:尽管几十年构的研究,但由蛋白质折叠和聚集(淀粉样物)引起的疾病治疗限于治疗症状,仅为患者提供暂时和中等的缓解。开发成功疾病改性药物的淀粉样蛋白剂的失败源于这些药物的靶标的本质 - 主要是淀粉样蛋白蛋白的低聚物,其与传统靶标不同,例如酶或受体。低聚物是稳定的,没有明确的结构,并且存在于动态变化的混合物中。因此,抑制这些低聚物的形成和毒性可能需要开箱即用的思维和新的策略。我们在这里审查了基于靶向疏水性和静电相互作用组合的策略的策略的发展,该抗液体和阳离子化蛋白的组装和毒性使用赖氨酸(k) - 特异性“分子镊子”(MTS)的毒性。我们的讨论包括对文献的调查,证明了K残基在淀粉样蛋白的组装和毒性中的重要作用以及蛋白质聚集的铅Mt衍生物的发育,从体外蛋白质聚集的抑制剂到药物候选物,显示出有效改善的药物阿尔茨海默氏症和帕金森病的动物模型中的疾病症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号